Cargando…

Advances in targeted therapy for acute myeloid leukemia

Acute myeloid leukemia (AML) is a clonal malignancy characterized by genetic heterogeneity due to recurrent gene mutations. Treatment with cytotoxic chemotherapy has been the standard of care for more than half of a century. Although much progress has been made toward improving treatment related mor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Jifeng, Jiang, Peter Y. Z., Sun, Hao, Zhang, Xia, Jiang, Zhongxing, Li, Yingmei, Song, Yongping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238648/ https://www.ncbi.nlm.nih.gov/pubmed/32477567 http://dx.doi.org/10.1186/s40364-020-00196-2

Ejemplares similares

Clinical implications of recurrent gene mutations in acute myeloid leukemia
por: Yu, Jifeng, et al.
Publicado: (2020)

Significance of bone marrow fibrosis in acute myeloid leukemia for survival in the real-world
por: Zhang, Xia, et al.
Publicado: (2022)

Deficient Regulatory Innate Lymphoid Cells and Differential Expression of miRNAs in Acute Myeloid Leukemia Quantified by Next Generation Sequence
por: Yu, Jifeng, et al.
Publicado: (2019)

Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia
por: Yu, Jifeng, et al.
Publicado: (2020)

Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy
por: Cao, Weijie, et al.
Publicado: (2022)

Targeting CD47 for cancer immunotherapy
por: Jiang, Zhongxing, et al.
Publicado: (2021)

Single-cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment
por: Guo, Rongqun, et al.
Publicado: (2021)

Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives
por: Sun, Hao, et al.
Publicado: (2022)

Correction: Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives
por: Sun, Hao, et al.
Publicado: (2022)

Recent advances in targeted therapies in acute myeloid leukemia
por: Bhansali, Rahul S., et al.
Publicado: (2023)

Research progress on dendritic cell vaccines in cancer immunotherapy
por: Yu, Jifeng, et al.
Publicado: (2022)

Clinical Characteristics And Outcome Of Biphenotypic Acute Leukemia: 10 Case Reports And Literature Review
por: Yu, Jifeng, et al.
Publicado: (2019)

Recent advances of targeted therapy in relapsed/refractory acute myeloid leukemia
por: Ma, Jiale, et al.
Publicado: (2021)

Mutational spectrum and prognosis in NRAS-mutated acute myeloid leukemia
por: Wang, Shujuan, et al.
Publicado: (2020)

Applications of gut microbiota in patients with hematopoietic stem-cell transplantation
por: Yu, Jifeng, et al.
Publicado: (2020)

Resistance to targeted therapies in acute myeloid leukemia
por: Mecklenbrauck, Rabea, et al.
Publicado: (2022)

Targeted Therapy Development in Acute Myeloid Leukemia
por: Totiger, Tulasigeri M., et al.
Publicado: (2023)

An Overview of Targeted Therapies in Acute Myeloid Leukemia
por: Turkalj, Sven, et al.
Publicado: (2023)

Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia)
por: Lin, Min, et al.
Publicado: (2018)

Maintenance therapy in acute myeloid leukemia: advances and controversies
por: Senapati, Jayastu, et al.
Publicado: (2023)

miRNAs in acute myeloid leukemia
por: Liao, Qiong, et al.
Publicado: (2016)

Molecular landscape and targeted therapy of acute myeloid leukemia
por: Gu, Runxia, et al.
Publicado: (2018)

Targeting CLL-1 for acute myeloid leukemia therapy
por: Ma, Hongbing, et al.
Publicado: (2019)

Targeting CD33 for acute myeloid leukemia therapy
por: Liu, Jingjing, et al.
Publicado: (2022)

Molecular-Targeted Therapy of Pediatric Acute Myeloid Leukemia
por: Obszański, Piotr, et al.
Publicado: (2022)

Generation and clinical potential of functional T lymphocytes from gene-edited pluripotent stem cells
por: Guo, Rongqun, et al.
Publicado: (2022)

Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019)

Risk factors affect accurate prognosis in ASXL1-mutated acute myeloid leukemia
por: Fan, Yi, et al.
Publicado: (2021)

Acute Myeloid Leukemia: Advancements in Diagnosis and Treatment
por: Yu, Meng-Ge, et al.
Publicado: (2017)

Inhibition of CSRP2 Promotes Leukemia Cell Proliferation and Correlates with Relapse in Adults with Acute Myeloid Leukemia
por: Wang, Shujuan, et al.
Publicado: (2020)

Advances in treating acute myeloid leukemia
por: Showel, Margaret M., et al.
Publicado: (2014)

Prognostic prediction of novel risk scores (AML-DRG and AML-HCT-CR) in acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation
por: Cao, Weijie, et al.
Publicado: (2022)

Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
por: Wei, Yunxiong, et al.
Publicado: (2020)

Near-infrared oxidative phosphorylation inhibitor integrates acute myeloid leukemia–targeted imaging and therapy
por: Zhang, Chi, et al.
Publicado: (2021)

Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019)

Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1
por: Han, Lijie, et al.
Publicado: (2022)

Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy
por: Castelli, Germana, et al.
Publicado: (2017)

Targeted Therapies for the Evolving Molecular Landscape of Acute Myeloid Leukemia
por: Ahmadmehrabi, Khashayar, et al.
Publicado: (2021)

Epigenetic modifications and targeted therapy in pediatric acute myeloid leukemia
por: Xu, Huan, et al.
Publicado: (2022)

Bispecific antibody-targeted T-cell therapy for acute myeloid leukemia
por: Kubicka, Ewa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rt2fc15flheam5l0cuahramhhp